Expected Outcome of Untreated Monosomy 7

Natural History by Disease Context

• The International Prognostic Scoring System (IPSS) recommends that untreated high-risk and very high-risk patients with Myelodysplastic Syndrome (MDS) and monosomy 7 have a median overall survival of 13-21 months 1
• The American Society of Hematology notes that the median time to Acute Myeloid Leukemia (AML) evolution is 0.8-1.6 years for patients with MDS and monosomy 7, with very high-risk patients progressing in 0.8 years and high-risk patients in 1.6 years 1

Mechanisms of Disease Progression

• Approximately 50% of patients with monosomy 7 acquire additional leukemia-driver mutations, including SETBP1, ASXL1, RUNX1, and RAS pathway genes, which accelerate progression to acute leukemia, according to the National Comprehensive Cancer Network 2, 3
• The presence of complex karyotypes (≥3 abnormalities) alongside monosomy 7 confers the worst prognosis with median survival of only 13 months, as stated by the European Society for Medical Oncology 1

Clinical Manifestations Leading to Death

• Bone marrow failure manifesting as severe cytopenias with life-threatening infections, bleeding, and transfusion-dependent anemia is a common cause of death in patients with monosomy 7, as reported by the American Society of Clinical Oncology 4
• Progression to acute leukemia occurs in the majority of MDS cases, with blast counts rising inexorably, according to the American College of Physicians 1

Comparative Outcomes: Untreated vs. Treated

• The European Society for Medical Oncology recommends that azacitidine treatment extends median survival to 25 months for high-risk patients with monosomy 7, compared to 21 months for untreated patients 1
• Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) dramatically improves outcomes to 40 months median survival for high-risk patients and 31 months for very high-risk patients, representing a 2-3 fold improvement over no treatment, as stated by the American Society of Hematology 1

Special Population Considerations

• Patients with germline predisposition syndromes, such as GATA2 deficiency, Fanconi Anemia, or SAMD9/SAMD9L mutations, who develop monosomy 7 have particularly aggressive disease with rapid progression to AML if untreated, according to the National Cancer Institute 2, 3

Monosomy 7: Evidence‑Based Clinical Facts

Epidemiology & Prognostic Significance

• Monosomy 7 is identified in approximately 10 % of myelodysplastic syndrome (MDS) cases and is regarded as one of the most adverse cytogenetic abnormalities, indicating clonal disease even when morphologic dysplasia is absent. 5

Diagnostic Recommendations

• At diagnosis, conventional cytogenetic analysis should examine at least 20 metaphases to detect monosomy 7 and any accompanying chromosomal abnormalities. 5
• Fluorescence in‑situ hybridization (FISH) should be employed when conventional karyotyping is inconclusive or to clarify complex cytogenetic findings. 5

Co‑Occurring High‑Risk Somatic Mutations

• About half of patients with monosomy 7 acquire additional high‑risk somatic mutations—most commonly in SETBP1, ASXL1, RUNX1, and genes of the RAS signaling pathway—which accelerate progression to acute leukemia. 6

Pediatric Acute Myeloid Leukemia (AML) Risk Classification

• In pediatric AML, monosomy 7 is classified as an adverse‑risk cytogenetic abnormality and must be distinguished from del(7q), which is associated with comparatively better outcomes. 7

Myelodysplastic Syndrome (MDS) Risk Stratification

• The coexistence of monosomy 7 (or del(7q)) with del(5q) removes patients from the favorable‑risk del(5q) MDS category, reclassifying them as having an adverse prognosis. 8

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Monosomy 7

Indication for Transplant

• In individuals younger than 55 years, without severe comorbidities, who have high‑risk cytogenetic abnormalities that include monosomy 7, a myeloablative allogeneic HSCT from a fully HLA‑matched sibling donor should be performed during the first complete remission. 9

Molecular and Germline Evaluation in Monosomy 7 Myelodysplastic Syndromes and Acute Myeloid Leukemia

Molecular Testing for High‑Risk Somatic Mutations

• In patients with monosomy 7‑associated MDS/AML, the NCCN recommends comprehensive molecular profiling for high‑risk somatic mutations (e.g., SETBP1, ASXL1, RUNX1, and RAS‑pathway genes), because roughly 50 % of these patients acquire such mutations, which are linked to accelerated progression to acute leukemia【10】.

Germline Predisposition Screening

• The NCCN advises evaluation for germline predisposition syndromes—particularly GATA2 deficiency (MonoMAC or Emberger syndrome)—in individuals with monosomy 7, as the combination of monosomy 7 and somatic ASXL1 mutations frequently appears at disease transformation in this subgroup【11】.

• Additionally, the NCCN recommends targeted germline testing for genes such as RUNX1, ETV6, FANCA‑FANCM (Fanconi anemia genes), DDX41, and other familial leukemia‑predisposition genes when clinical features (e.g., thrombocytopenia, immunodeficiency, characteristic physical findings, or relevant family history) suggest an inherited syndrome【11】.